These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26173559)

  • 21. Regulated competition in health care: switching and barriers to switching in the Dutch health insurance system.
    Reitsma-van Rooijen M; de Jong JD; Rijken M
    BMC Health Serv Res; 2011 May; 11():95. PubMed ID: 21569225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statutory health insurance competition in Europe: a four-country comparison.
    Thomson S; Busse R; Crivelli L; van de Ven W; Van de Voorde C
    Health Policy; 2013 Mar; 109(3):209-25. PubMed ID: 23395277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preferred providers and the credible commitment problem in health insurance: first experiences with the implementation of managed competition in the Dutch health care system.
    Boonen LH; Schut FT
    Health Econ Policy Law; 2011 Apr; 6(2):219-35. PubMed ID: 21122187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results of the market-oriented reform in the Netherlands: a review.
    Maarse H; Jeurissen P; Ruwaard D
    Health Econ Policy Law; 2016 Apr; 11(2):161-78. PubMed ID: 26278627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching costs in competitive health insurance markets: The role of insurers' pricing strategies.
    Lamiraud K; Stadelmann P
    Health Econ; 2020 Sep; 29(9):992-1012. PubMed ID: 32542729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consumer channeling by health insurers: natural experiments with preferred providers in the Dutch pharmacy market.
    Boonen LH; Schut FT; Koolman X
    Health Econ; 2008 Mar; 17(3):299-316. PubMed ID: 17647296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new prevention paradox: the trade-off between reducing incentives for risk selection and increasing the incentives for prevention for health insurers.
    Kanters TA; Brouwer WB; van Vliet RC; van Baal PH; Polder JJ
    Soc Sci Med; 2013 Jan; 76(1):150-8. PubMed ID: 23182593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What can Europe learn from the managed care backlash in the United States?
    Duijmelinck D; van de Ven W
    Health Policy; 2016 May; 120(5):509-18. PubMed ID: 27055353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How is enrollees' trust in health insurers associated with choosing health insurance?
    van der Hulst FJP; Brabers AEM; de Jong JD
    PLoS One; 2023; 18(11):e0292964. PubMed ID: 37917768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overpaying morbidity adjusters in risk equalization models.
    van Kleef RC; van Vliet RC; van de Ven WP
    Eur J Health Econ; 2016 Sep; 17(7):885-95. PubMed ID: 26420555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is the medical loss ratio a good target measure for regulation in the individual market for health insurance?
    Karaca-Mandic P; Abraham JM; Simon K
    Health Econ; 2015 Jan; 24(1):55-74. PubMed ID: 24123608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consumer choice among Mutual Healthcare Purchasers: a feasible option for China?
    Xu W; van de Ven WP
    Soc Sci Med; 2013 Nov; 96():277-84. PubMed ID: 23261255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hospital prices and market structure in the hospital and insurance industries.
    Moriya AS; Vogt WB; Gaynor M
    Health Econ Policy Law; 2010 Oct; 5(4):459-79. PubMed ID: 20478106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The key role of health insurance in a cost-effective health care system. Towards regulated competition in the Dutch medical market.
    van de Ven WP
    Health Policy; 1987 Apr; 7(2):253-72. PubMed ID: 10312077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving risk equalization for individuals with persistently high costs: Experiences from the Netherlands.
    Eijkenaar F; van Vliet RCJA
    Health Policy; 2017 Nov; 121(11):1169-1176. PubMed ID: 28942090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advice from the health insurer as a channelling strategy: a natural experiment at a Dutch health insurance company.
    Bes RE; Curfs EC; Groenewegen PP; de Jong JD
    BMC Health Serv Res; 2018 Nov; 18(1):832. PubMed ID: 30400978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Managed competition in the Netherlands-a qualitative study.
    Heinemann S; Leiber S; Gress S
    Health Policy; 2013 Feb; 109(2):113-21. PubMed ID: 23031431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Choice determinants of the mobility in the Dutch health insurance market.
    Mosca I; Schut-Welkzijn A
    Eur J Health Econ; 2008 Aug; 9(3):261-4. PubMed ID: 17851703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health plan choice in the Netherlands: restrictive health plans preferred by young and healthy individuals.
    Bes RE; Curfs EC; Groenewegen PP; de Jong JD
    Health Econ Policy Law; 2017 Jul; 12(3):345-362. PubMed ID: 28290918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Designing and regulating health insurance exchanges: lessons from Massachusetts.
    Ericson KM; Starc A
    Inquiry; 2012-2013 Winter; 49(4):327-38. PubMed ID: 23469676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.